About your Search

20121129
20121207
Search Results 0 to 1 of about 2
rubio, mccaskill and whitehouse to introduce amendment 3017 to curb the out-of-pocket prescription drug costs proposed to tricare beneficiaries. the department of defense has proposed increase in co-payments for tricare beneficiaries. in some cases, co-payments could almost double or even triple. for example, under the proposal, the out-of-pocket costs for a brand-name drug picked up at a local pharmacy would more than double, increasing from $12 to $26. ensuring the fiscal soundness of tricare is critical but we should limit the burden on beneficiaries in our efforts to shore up the problem. this amendment would cush the out-of-pocket prescription drug costs proposed for tricare beneficiaries. for instance, instead of paying $26 for a brand-name drug, a tricare beneficiary would pay $17 at a retail pharmacy, a $5 increase from last year, as opposed to a $14 increase. and d.o.d. would be prohibited from instituting dramatic increases in prescription drug co-payments in future years. co-payments could only increase at the rate of the annual cost-of-living adjustment, or cola. to protect
, collins, crapo, grassley, heller, hutchison, isakson, kirk, lugar, moran, murkowski, rubio, snowe, and wicker, in addition to all of my democratic cosponsors. this is also a bill that has the support of the american cancer society, the pancreatic cancer action network, the lung cancer alliance, and the american association for medical research as well as the american association of medical colleges. what the bill does is asks that the national institutes of health convene and evaluate a discussion about what we call recalcitrant cancers. this actually began as a pancreatic cancer research bill, but it became apparent that there were other cancers we group now in what we call recalcitrant cancers in that they have not responded to treatment in research and they remain cancers for which there has been little progress in survivability. and because they are so deadly and so lethal, we're trying to direct a little bit more attention out of n.i.h. towards research on these cancers. for me, this has a personal component, as i know it does for many people who have been touched by pancreat
Search Results 0 to 1 of about 2